Our COVID-19 vaccine agreements

New Zealand has signed agreements with 4 pharmaceutical companies to purchase COVID-19 vaccines, if they are proven to be safe and effective.

Latest updates

The teams working on the vaccination rollout are separate to those who are responding to any community outbreaks of COVID-19. 

The roll out of the vaccination programme to MIQ and the border workforce is progressing well, and we don’t expect any slow-down as a result of the change in Alert Levels.

Vaccines we have agreed to purchase

We have entered into the following agreements for the supply of COVID-19 vaccines. Investing in a range of vaccines gives us more choice – especially if some vaccines are more suited to particular population groups.

All agreements are subject to the vaccines successfully completing all clinical trials and passing regulatory approvals in New Zealand before they will be provided to the community.

Pfizer and BioNTech (Comirnaty)

Type of vaccine: mRNA-based vaccine
Doses needed: 2
Number of doses agreed to: 1.5 million

Learn more about the Pfizer and BioNTech vaccine

Janssen Pharmaceutica

Type of vaccine: Viral vector vaccine
Doses needed: 1
Number of doses agreed to: Up to 5 million

Agreement advanced to purchase up to 5 million COVID-19 vaccines (external link)

University of Oxford and AstraZeneca

Type of vaccine: Viral vector vaccine
Doses needed: 2
Number of doses agreed to: 7.6 million

Two new vaccines secured, enough for every New Zealander (external link)

Novavax

Type of vaccine: Protein subunit vaccine
Doses needed: 2
Number of doses agreed to: 10.72 million

Two new vaccines secured, enough for every New Zealander (external link)

Last updated: